Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease
Jeffrey S. Hyams(Connecticut Children's Medical Center), Meena Thayu(Children's Hospital of Philadelphia), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Johanna C. Escher(Erasmus MC - Sophia Children’s Hospital), Robert N. Baldassano(Children's Hospital of Philadelphia), Chu Ri Shin(Janssen Scientific Affairs (United States)), Frank M. Ruemmele(Délégation Paris 5), Gigi Veereman, Nicholas Masel, Salvatore Cucchiara(Massachusetts General Hospital), Sibylle Koletzko(LMU Klinikum), Anne M. Griffiths(University of Toronto), Harland S. Winter(Massachusetts General Hospital), Richard B. Colletti(Greenville College), James Markowitz(Philadelphia University), Benjamin D. Gold(Emory University), Kezhen L. Tang(Janssen (United States)), Subra Kugathasan(Children's Healthcare of Atlanta), John Fell(Chelsea and Westminster Hospital), William A. Faubion(Mayo Clinic in Arizona)
Cited by 217
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k